Wells Fargo cuts Pershing Square target to $34
Wells Fargo lowered its price target for Pershing Square to $34 while maintaining an Equal-Weight rating, reflecting the fund's 9.3% decline this year. The underperformance contrasts with gains in the S&P 500 and Nasdaq 100, as well as other hedge funds like Point72 and Millennium. Analysts from Citigroup and RBC Capital have also reduced their price targets on the stock.
*this image is generated using AI for illustrative purposes only.
Wells Fargo analyst Robert Ryan has maintained an Equal-Weight rating on Pershing Square while lowering the price target to $34 from $37. This revision follows a period of significant underperformance for Bill Ackman's hedge fund, which has seen its portfolio drop by 9.3% this year. The decline contrasts sharply with the broader U.S. stock market, as the S&P 500 and Nasdaq 100 indices jumped by 9.6% and 13.4% respectively over the same period.
Analyst Ratings and Price Targets
The adjustment by Wells Fargo aligns with a broader trend of reduced expectations among analysts covering the firm. Previously, Citigroup analyst Matthew Heimermann maintained a Buy rating but lowered the price target to $45 from $50. Similarly, RBC Capital analyst Kenneth S. Lee kept a Sector Perform rating while reducing the price target to $38 from $40.
| Firm | Rating | Price Target |
|---|---|---|
| Wells Fargo | Equal-Weight | $34 |
| Citigroup | Buy | $45 |
| RBC Capital | Sector Perform | $38 |
Portfolio Performance and Market Comparison
Pershing Square's struggles have been pronounced compared to its peers. While the fund lagged, Point72 and Millennium gained 14.5% and 10.5% in the first half of the year, respectively. Pinpoint Asset Management and Dymon Asia returned 16.9% and 15%. Key holdings contributing to the fund's underperformance include Brookfield Corporation, which dropped by 5.3% since January, while Amazon rose by 6.8% and Microsoft remained under pressure.
Net Worth and Historical Context
The market declines have impacted Ackman's net worth, which fell to $10 billion after peaking at $14.3 billion earlier this year. Pershing Square Inc stock has fallen to $34 from an all-time high of $54, and Pershing Square USA is hovering near its all-time low of $36.75. In the UK, Pershing Square Holdings has dropped by 25% from its highest point this year. Despite the current slump, Ackman has a history of recoveries, including a 70% return in 2020, though he previously faced significant losses in Valeant Pharmaceuticals and Herbalife.
What strategic shifts might Pershing Square consider to reverse its recent underperformance relative to the broader market?
How could continued underperformance impact investor confidence and capital inflows into Pershing Square's funds?
What are the potential risks or opportunities for Pershing Square's key holdings, such as Brookfield Corporation, in the current market environment?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
